CAS 461432-26-8
:Dapagliflozin
Description:
Dapagliflozin is a medication primarily used in the management of type 2 diabetes mellitus. It belongs to the class of drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors, which work by preventing the reabsorption of glucose in the kidneys, thereby promoting its excretion in urine and lowering blood glucose levels. The chemical formula of dapagliflozin is C21H25ClO6S, and it features a sulfonyl group, a chlorophenyl moiety, and a glucose-like structure that facilitates its mechanism of action. Dapagliflozin is typically administered orally and is often prescribed in conjunction with other antidiabetic agents to enhance glycemic control. In addition to its glucose-lowering effects, it has been associated with weight loss and a reduction in blood pressure. Common side effects may include urinary tract infections and genital mycotic infections due to increased glucose in the urine. Overall, dapagliflozin represents a significant advancement in diabetes treatment, offering a unique approach to managing blood sugar levels.
Formula:C21H25ClO6
InChI:InChI=1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1
InChI key:InChIKey=JVHXJTBJCFBINQ-ADAARDCZSA-N
SMILES:O[C@H]1[C@@H](O[C@H](CO)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC=C(OCC)C=C3)=C(Cl)C=C2
Synonyms:- (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-<span class="text-smallcaps">D</span>-glucitol
- (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol
- (1S)-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D-glucitol
- <span class="text-smallcaps">D</span>-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1S)-
- Bms-512148
- D-Glucitol, 1,5-Anhydro-1-C-[4-Chloro-3-[(4-Ethoxyphenyl)Methyl]Phenyl]-, (1S)-
- Dapagliflozin
- Dapagliflozin free base
- (2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
Filter by
Purity percentage
0
100
|
0
|
50
|
90
|
95
|
100
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
Dapagliflozin
CAS:Formula:C21H25ClO6Purity:>95.0%(HPLC)Color and Shape:White to Light yellow powder to crystalMolecular weight:408.88(2S,3R,4R,5S,6R)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(hydroxymethyl)oxane-3,4,5-triol
CAS:Formula:C21H25ClO6Purity:97%Color and Shape:SolidMolecular weight:408.8726Ref: IN-DA0039GJ
1kgTo inquire5gTo inquire500gTo inquire10mg27.00€50mg28.00€100mg49.00€250mg52.00€1g107.00€10g552.00€250g659.00€Dapagliflozin
CAS:Formula:C21H25ClO6Purity:≥ 98.0% (dried basis)Color and Shape:White to light-yellow powderMolecular weight:408.87Dapagliflozin (Standard)
CAS:Dapagliflozin (Standard) is the standard for Dapagliflozin (T2389). Dapagliflozin is a competitive sodium-glucose cotransporter 2 (SGLT2) inhibitor that can reduce renal glucose reabsorption and promote urinary glucose excretion. Dapagliflozin can also inhibit renal mesangial cell fibrosis by regulating the HO-1/TGF-β1/Smad2/3 axis, and is related to research on glucose transport, renal cell responses, and fibrosis signaling. Dapagliflozin can also be used in research on SGLT2 pharmacology and mechanisms of renal fibrosis-related pathways.Formula:C21H25ClO6Molecular weight:408.87Dapagliflozin
CAS:Stability Hygroscopic
Applications A sodium-glucose transporter 2 inhibitor.
References Kasichayanula, S. et al.: Diabetes, Obesity and Metabolism 13, 47 (2011)Formula:C21H25ClO6Color and Shape:NeatMolecular weight:408.87Dapagliflozin
CAS:(2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triolFormula:C21H25ClO6Purity:97%Molecular weight:408.87Dapagliflozin
CAS:Dapagliflozin (BMS-512148) is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity.Formula:C21H25ClO6Purity:99.5% - 99.97%Color and Shape:SolidMolecular weight:408.87Dapagliflozin - Bio-X ™
CAS:Dapagliflozin is a sodium-glucose cotransporter subtype 2 (SGLT2) inhibitor that can be used in the treatment of diabetes mellitus type 2. It inhibits glucose reabsorption in the proximal tubule of the nephron and results in glycosuria, which helps to improve glycaemic control. Also, Dapagliflozin is used to lower the risk of sustained eGFR decline, end-stage renal disease, cardiovascular death, and hospitalization for heart failure in patients with chronic kidney disease who are at risk of progression.Formula:C21H25ClO6Purity:Min. 99 Area-%Color and Shape:PowderMolecular weight:408.87 g/molDapagliflozin
CAS:Dapagliflozin is a sodium-glucose cotransporter subtype 2 (SGLT2) inhibitor that can be used in the treatment of diabetes mellitus type 2. SGLT2 is located in the proximal convoluted tubule and when it is inhibited the reabsorption of glucose into the kidneys is prevented and instead glucose is excreted in the urine. As a result glucose levels are reduced. Dapagliflozin is metabolized into to its inactive metabolite 3-O-glucuronide by the UGT1A9 enzyme present in the liver and the kidneys. In addition, dapagliflozin has been shown to cause weight loss and decrease the risk of cardiovascular events such as congestive heart failure.Formula:C21H25ClO6Purity:Min. 98 Area-%Color and Shape:White Yellow PowderMolecular weight:408.87 g/mol
![(2S,3R,4R,5S,6R)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(hydroxymethyl)oxane-3,4,5-triol](https://static.cymitquimica.com/products/IN/thumb/DA0039GJ.jpg)
